<DOC>
	<DOC>NCT01757691</DOC>
	<brief_summary>To evaluate the efficacy and safety of fingolimod 0.5mg versus placebo in patients with suspected acute demyelinating optic neuritis (ADON) receiving standard steroid treatment</brief_summary>
	<brief_title>Fingolimod (FTY720) in Acute Demyelinating Optic Neuritis (ADON)</brief_title>
	<detailed_description />
	<mesh_term>Optic Neuritis</mesh_term>
	<mesh_term>Neuritis</mesh_term>
	<mesh_term>Fingolimod Hydrochloride</mesh_term>
	<criteria>Clinical signs and symptoms of ADON in one eye (loss of vision, pain on movement, impairment of color vision) First episode of ADON Able to undergo treatment with IV steroids History of any unexplained eye or neurological symptoms lasting longer than 48 hours Optic neuritis in both eyes Concomitant condition in either eye, other than optic neuritis History of heart condition/disease Patients with uncontrolled diabetes mellitus Patients with liver conditions/disease Inability to undergo MRI Pregnant or nursing women Women of childbearing potential who are not using highly effective method of birth control Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Acute demyelinating optic neuritis</keyword>
	<keyword>Optic neuritis</keyword>
</DOC>